Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pretax income is the income that a company earns before paying income taxes. Jacobio Pharmaceuticals Group Co's pretax income for the
six
months ended in Jun. 2026 was $87.5 Mil.
Its pretax income for the trailing twelve months (TTM) ended in Jun. 2026 was $75.4 Mil.
Jacobio Pharmaceuticals Group Co's pretax margin was 82.18%.
During the past 8 years, Jacobio Pharmaceuticals Group Co's highest Pretax Margin was 70.10%. The lowest was -565.36%. And the median was -292.01%.
During the past 8 years, Jacobio Pharmaceuticals Group Co's highest Pretax Margin was 70.10%. The lowest was -565.36%. And the median was -292.01%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jacobio Pharmaceuticals Group Co Pre-Tax Income Related Terms
Jacobio Pharmaceuticals Group Co Pre-Tax Income Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jacobio Pharmaceuticals Group Co Pre-Tax Income Chart
JBPHF vs VRTX, REGN, MRNA: Pre-Tax Income Comparison
For the Biotechnology subindustry, Jacobio Pharmaceuticals Group Co's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jacobio Pharmaceuticals Group Co Pre-Tax Income vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Jacobio Pharmaceuticals Group Co's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where Jacobio Pharmaceuticals Group Co's Pre-Tax Income falls into.
Pre-Tax Income for the trailing twelve months (TTM) ended in Jun. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was $75.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jacobio Pharmaceuticals Group Co (JBPHF) has a Pre-Tax Income of $75.4 Mil as of Jun. 2026. Pre-Tax Income is the total earnings before taxes but after all operating and interest expenses. View historical data on Jacobio Pharmaceuticals Group Co and its competitors.
Is Jacobio Pharmaceuticals Group Co's Pre-Tax Income too high?
Jacobio Pharmaceuticals Group Co's current Pre-Tax Income is $75.4 Mil. Overall, Jacobio Pharmaceuticals Group Co has a GF Score™ of 32/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Jacobio Pharmaceuticals Group Co's Pre-Tax Income compare to VRTX and REGN?
Jacobio Pharmaceuticals Group Co's Pre-Tax Income of $75.4 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pre-Tax Income for a Biotechnology company?
A good Pre-Tax Income depends on the Biotechnology industry context. However, Pre-Tax Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pre-Tax Income mean?
A high Pre-Tax Income can signal that a stock is expensive relative to its fundamentals. Pre-Tax Income is the total earnings before taxes but after all operating and interest expenses. View historical data on Jacobio Pharmaceuticals Group Co and its competitors. Jacobio Pharmaceuticals Group Co's current Pre-Tax Income is $75.4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jacobio Pharmaceuticals Group Co stock overvalued right now?
Based on GuruFocus' analysis, Jacobio Pharmaceuticals Group Co (JBPHF) is currently considered Possible Value Trap. The stock's GF Value™ is $5.61, compared to a current price of $0.72 — trading 87.1% below its estimated fair value. The current Pre-Tax Income is $75.4 Mil. Jacobio Pharmaceuticals Group Co's overall GF Score™ is 32/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pre-Tax Income calculated?
Pre-Tax Income is calculated from a company's financial statements. For Jacobio Pharmaceuticals Group Co (JBPHF), the current Pre-Tax Income is $75.4 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jacobio Pharmaceuticals Group Co (JBPHF) Overvalued in 2026?
Based on GuruFocus' analysis, Jacobio Pharmaceuticals Group Co stock appears to be undervalued.
The current stock price of $0.72 is trading 87.1% below its estimated GF Value™ of $5.61.
GuruFocus considers Jacobio Pharmaceuticals Group Co to be Possible Value Trap.
Key valuation signals for JBPHF:
Pre-Tax Income: $75.4 Mil
GF Value™: $5.61 vs. price of $0.72 (87.1% below fair value)
No single metric tells the full story. See the JBPHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jacobio Pharmaceuticals Group Co Ltd is a clinical-stage pharmaceutical company focusing on the in-house discovery and development of oncology therapies. The company is engaged in developing breakthrough cancer therapies for patients. The producst pipeline of the company includes KRAS G12C inhibitor, SHP2 inhibitor, Pan-KRAS inhibitor, KRAS G12D ADC JAB-BX600, Aurora Kinase A (AURKA) inhibitor, BET inhibitor, P53 Y220C mutant proteins, and others.
32GF Score
Get the complete analysis for JBPHF
Pre-Tax Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
JBPHF has been successfully added to your 
